Paychex(PAYX) Newsfilter·2025-01-13 18:59Merger and Acquisition Deals - Enfusion Inc (NYSE: ENFN) is set to be acquired by Clearwater Analytics (NYSE: CWAN) for $11.25 per share in cash, valuing the deal at approximately $1.5 billion [2] - Intra-Cellular Therapies Inc (Nasdaq: ITCI) will be acquired by Johnson & Johnson (NYSE: JNJ) for $132.00 per share in cash, with a total equity value of approximately $14.6 billion [4] - Paycor HCM Inc (Nasdaq: PYCR) is to be acquired by Paychex Inc (NASDAQ: PAYX) for $22.50 per share in cash, representing an enterprise value of approximately $4.1 billion [6] - Accolade Inc (Nasdaq: ACCD) will be acquired by Transcarent for $7.03 per share in cash, with an approximate equity value of $621 million [8] Investigations and Legal Concerns - Investigations are ongoing to determine if the boards of Enfusion, Intra-Cellular Therapies, Paycor HCM, and Accolade breached their fiduciary duties by failing to conduct a fair process and ensure shareholders receive fair value for their shares [2][4][6][8] - Additional information regarding the investigations can be found on Brodsky & Smith's website for each respective case [3][5][7][9] Legal Firm Background - Brodsky & Smith is a litigation law firm specializing in securities and class action lawsuits, with a track record of recovering millions of dollars for clients and shareholders [10]